<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171205037760N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-08</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Association the combined and separate effects of the DASH diet and vitamin D supplementation on inflammatory markers and improvement of heart condition in patients with heart failure</public_title>
      <acronym></acronym>
      <scientific_title>Association the combined and separate effects of the DASH diet and vitamin D supplementation on inflammatory markers and improvement of heart condition in patients with heart failure</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71762</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: In this study, to allocate people in the intervention and control groups, we use the block method and we use the eight block method, and according to this blocking, the chance of assigning people to each of the four groups will be the same. .
Our sample size is 120 people, 90 people will be in the intervention group and 30 people will be in the control group. Random allocation method is block classification using Stata software version 16. Blocking will be done by an epidemiologist.</study_design>
      <phase>3</phase>
      <hc_freetext>HEART FAILURE.</hc_freetext>
      <i_freetext>Intervention 1: In intervention 1, 30 patients received only vitamin D. The intake of vitamin D is once a week and its duration is for two months. The supplement is given to the patients by the researcher. The supplement will be provided by Dana Pharmaceutical Company, which is available in the food supplement market under the name of vitamin D3 under the brand name D Vigil and is approved by relevant organizations. Intervention 2: Intervention group 2: In this group, which is about 30 people, they receive DASH diet advice. This diet is based on the consumption of vegetables, fruits, low-fat dairy products and nuts. In this diet, the consumption of red meat, sweets and solid oil is reduced. Intervention 3: Intervention group 3: In this group, which has 30 people, they receive vitamin D and DASH diet at the same time. They receive vitamin D 50,000 every week for a period of two months. The supplement will be provided by Dana Pharmaceuticals, which is available in the nutritional supplement market under the name vitamin D3 under the brand name D Vigil, and the group will also receive DASH diet recommendations based on calorie needs. Intervention 4: Control group, which has 30 people, they receive placebo vitamin D. Placebo contains gel and is given to patients once a week for two months. This group of patients does not receive the DASH diet.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Laboratory results and clinical evaluations can be shared

When:
Access 6 months after results are printed

To whom:
Accessibility for academics

Conditions:
They are only allowed to study

Where to obtain:
researcher

How to obtain:
The application must be submitted through a scientific center to Isfahan University of Medical Sciences, Faculty of Nutrition

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masomeh Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan University of Medical Sciences, Isfahan School of Medical Sciences, Thousand Jarib Street</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7346181746</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>sadeghimasoumeh@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morteza Safavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan University of Medical Sciences, Faculty of Nutrition</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73441</zip>
        <telephone>009 09131181981</telephone>
        <email>safavimorteza@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to cooperate with the plan
40 to 65 years old
Patients with stage 1 of heart failure. In other words, patients with an %EF between 40 and 50 are included in the study.
The ability to consume food properly (in other words, those patients will be selected who have the ability to consume vegetables and fruits, for example, have teeth suitable for chewing, are not hospitalized, have the ability and ability to prepare food, and or someone prepares it for them)
Vitamin D levels less than 30 ng/ml</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy, breastfeeding, hospitalization and Malignancy
Use of nutritional supplements in the last 3 months
Following a special diet•
Chronic kidney disease
Consumption of vitamin D supplements in the last three months.
Patients who do not have normal levels of creatine and urea
People with moderate and severe %EF. In other words, people whose %EF is less than 40</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I50.33</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute on chronic diastolic (congestive) heart failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In intervention 1, 30 patients received only vitamin D. The intake of vitamin D is once a week and its duration is for two months. The supplement is given to the patients by the researcher. The supplement will be provided by Dana Pharmaceutical Company, which is available in the food supplement market under the name of vitamin D3 under the brand name D Vigil and is approved by relevant organizations.</i_keyword>
      <i_keyword>Intervention group 2: In this group, which is about 30 people, they receive DASH diet advice. This diet is based on the consumption of vegetables, fruits, low-fat dairy products and nuts. In this diet, the consumption of red meat, sweets and solid oil is reduced.</i_keyword>
      <i_keyword>Intervention group 3: In this group, which has 30 people, they receive vitamin D and DASH diet at the same time. They receive vitamin D 50,000 every week for a period of two months. The supplement will be provided by Dana Pharmaceuticals, which is available in the nutritional supplement market under the name vitamin D3 under the brand name D Vigil, and the group will also receive DASH diet recommendations based on calorie needs.</i_keyword>
      <i_keyword>Control group, which has 30 people, they receive placebo vitamin D. Placebo contains gel and is given to patients once a week for two months. This group of patients does not receive the DASH diet.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HsCRP: One of the heart risk markers used to help determine a person's risk. It will be measured using immunoturbidometry. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: laboratory measurements, It is measured by immunoturbidometry.</prim_outcome>
      <prim_outcome>ESR: erythrocyte sedimentation rate (ESR); It is an indirect measure of the degree of inflammation in the body. This test measures the sedimentation rate of red blood cells in a blood sample placed in a long, narrow, vertical tube. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: A long, narrow and vertical pipe is used for measuring. The result of the ESR test is recorded in millimeters and the duration of red blood cell sedimentation is considered. The normal level of this test is 0-29 for women and 0-22 for men.</prim_outcome>
      <prim_outcome>Assessment of malnutrition:Check possible malnutrition in patients during treatment. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: It is measured through Mini nutritional assessment questionnaire .</prim_outcome>
      <prim_outcome>What is blood pressure: Normal blood pressure is a vital function of the body. Blood pressure is the force that propels blood through our circulatory system, bringing oxygen or nutrients to tissues and organs through arteries. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: blood pressure monitor.</prim_outcome>
      <prim_outcome>Blood fat test or lipid profile is a combination of tests that are considered to check the risks of coronary heart disease and include markers (LDL, HDL, TRIGLYCERIDE, TOTAL CHOLESTEROL) or as a preventive measure to check risks related to factors such as: Eating habits, diet, stress, exercise and lifestyle are done. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: through laboratory kits for measuring LDL, HDL, THREE TRIGLYCERIDE, TOTAL CHOLESTEROL.</prim_outcome>
      <prim_outcome>Glucose reaches the body through food. After digesting carbohydrates, the body turns them into sugar that circulates in the blood. Blood sugar is necessary for the body to receive energy and is the so-called source of body energy. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: Blood glucose kit.</prim_outcome>
      <prim_outcome>Appetite is desire for food. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Cardiac exercise test is one of the necessary tests to check the heart's performance in active mode. The cardiologist requests this test to check the possibility of heart diseases in the patient. This test is one of the body checkup tests for people with heart problems. In this test, the patient usually walks on a regular treadmill according to the Bruce protocol or a similar exercise program, until the heart rate reaches the expected level or certain symptoms appear in the person. The process of performing this test is that heart function and blood pressure are checked in the exercise test, before, during and after the exercise test. These tests help the doctor to diagnose the problem. Timepoint: At the beginning of the study and two months after the intervention. Method of measurement: First, the pulse, blood pressure and heart rate are measured and then they are measured and recorded repeatedly during the test. After the heart examination, it will be placed on the treadmill for the exercise test. This device is a movable and rolling rubber plate (similar to a conveyor) on which the patient stands and must walk on it to maintain balance. Every 3 minutes, the slope of the strip will increase by 2% and its speed will increase by 1.2 km per hour.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-31</approval_date>
        <contact_name>Ethics committee of Eefahan University of Medical Sciences</contact_name>
        <contact_address>Hazar Jarib Street, Isfahan University of Medical Sciences Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
